Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343146 | 0.71 | GRM2 (0.41) | GRM2 | |
| SCHEMBL3340150 | 0.69 | KDM4E (0.51) | GRM2 | |
| SCHEMBL4473874 | 0.67 | PIM1 (0.41) | GRM2LMNALCK | |
| SCHEMBL3341721 | 0.67 | KDM4E (0.33) | — | |
| SCHEMBL11942291 | 0.65 | LMNA (0.47) | GRM2LMNADPP4DPP8 | |
| SCHEMBL7718641 | 0.63 | LMNA (0.54) | GRM2LMNA | |
| SCHEMBL3999989 | 0.63 | NOS3 (0.46) | GRM2LMNADPP4DPP8 | |
| SCHEMBL20674054 | 0.62 | GRM2 (0.39) | GRM2LMNADPP4DPP8LCK | |
| SCHEMBL27642254 | 0.62 | GRM2 (0.65) | GRM2 | |
| SCHEMBL16751985 | 0.62 | LMNA (0.44) | GRM2LMNADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | claimed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | GRM2 337/4885LMNA 2695/4885DPP4 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.